Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy.
10.1097/CM9.0000000000003703
- Author:
Yue PENG
1
;
Min YU
2
;
Bozhao LI
3
;
Siyu ZHANG
4
;
Jin CHENG
3
;
Feifan WU
5
;
Shuailun DU
3
;
Jinbai MIAO
1
;
Bin HU
1
;
Igor A OLKHOVSKY
6
;
Suping LI
3
Author Information
1. Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
2. Department of Stomatology, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, China.
3. CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
4. Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
5. Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital; Medical School of Chinese PLA, Beijing 100853, China.
6. Department of Hematology, National Research Center for Hematology, Ministry of Health, Krasnoyarsk, 660036, Russian Federation.
- Publication Type:Review
- Keywords:
Cancer therapy;
Chemotherapy;
Drug delivery;
Immunotherapy;
Nanomedicine;
Radiotherapy;
Tumor microenvironment
- MeSH:
Humans;
Neoplasms/radiotherapy*;
Immunotherapy/methods*;
Nanoparticles/chemistry*;
Animals;
Nanomedicine/methods*;
Drug Delivery Systems/methods*;
Drug Carriers/chemistry*;
Radiotherapy/methods*
- From:
Chinese Medical Journal
2025;138(16):1927-1944
- CountryChina
- Language:English
-
Abstract:
Cancer represents a major worldwide disease burden marked by escalating incidence and mortality. While therapeutic advances persist, developing safer and precisely targeted modalities remains imperative. Nanomedicines emerges as a transformative paradigm leveraging distinctive physicochemical properties to achieve tumor-specific drug delivery, controlled release, and tumor microenvironment modulation. By synergizing passive enhanced permeation and retention effect-driven accumulation and active ligand-mediated targeting, nanoplatforms enhance pharmacokinetics, promote tumor microenvironment enrichment, and improve cellular internalization while mitigating systemic toxicity. Despite revolutionizing cancer therapy through enhanced treatment efficacy and reduced adverse effects, translational challenges persist in manufacturing scalability, longterm biosafety, and cost-efficiency. This review systematically analyzes cutting-edge nanoplatforms, including polymeric, lipidic, biomimetic, albumin-based, peptide engineered, DNA origami, and inorganic nanocarriers, while evaluating their strategic advantages and technical limitations across three therapeutic domains: immunotherapy, chemotherapy, and radiotherapy. By assessing structure-function correlations and clinical translation barriers, this work establishes mechanistic and translational references to advance oncological nanomedicine development.
